![Chun Yan Zhang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chun Yan Zhang
Direktor/Vorstandsmitglied bei Eluminex Biosciences (Suzhou) Ltd.
Profil
Chun Yan Zhang currently works at Eluminex Biosciences (Suzhou) Ltd., as Director.
Aktive Positionen von Chun Yan Zhang
Unternehmen | Position | Beginn |
---|---|---|
Eluminex Biosciences (Suzhou) Ltd.
![]() Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Eluminex Biosciences (Suzhou) Ltd.
![]() Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | Health Technology |